Influenza Vaccines for the 2024-2025 Season
The Food and Drug Administration (FDA), in collaboration with the World Health Organization (WHO), has directed influenza vaccine manufacturers to remove the B/Yamagata influenza virus strain from all influenza vaccines distributed in the United States, by the 2024/25 influenza season. Please review the following important updates:
- Sanofi will be working to transition their flu vaccines to the trivalent (TIV) formulation.
- This transition will not impact the pre-booking process, which has a deadline of April 19, 2024, to confirm your 2024-2025 flu vaccine reservation.
CPP will be communicating more details as more information about the implementation timeline for our members becomes available.
To review more details regarding this change please click
HERE.
Sanofi’s Beyfortus Reservation Program
Sanofi is surveying customers to gain some insight into what demand for Beyfortus might look like for the 2024-2025 RSV season. The Beyfortus Reservation Program will help your practice to prepare and plan ahead of the season. This program has three steps:
- Forecast and Submit Data (February-April)
- Reserve Doses and Schedule Shipments (July-August)
- Receive Shipments (September-February).
Customers who choose to participate in the program will enjoy specific
program benefits.
For more information, please contact your Sanofi representative.